Chronic Obstructive Pulmonary Disease
Conditions
Interventions
Intervention Group:The intervention comprised two core components delivered by clinical pharmacists: (1) Evidence-based prescription optimization: Pharmacists provided prescribing physicians with GOLD
Control Group:The control group received usual pharmaceutical care provided by outpatient pharmacists.
Sponsors
Fengdu County People's Hospital
Eligibility
Sex/Gender
All
Age
60 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. A clinical diagnosis of Chronic Obstructive Pulmonary Disease (COPD), established in accordance with both the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report and the 2021 Chinese Thoracic Society guidelines. 2. Age 60–80 years, with a clinically documented COPD duration exceeding one month and verified issues with inhaler selection or technique. 3. Possession of adequate literacy and cognitive ability to provide written informed consent, successfully complete all components of the 6-month educational intervention, and participate in scheduled follow-up evaluations. 4. Physical ability, as confirmed by baseline assessment, to handle and operate inhaler devices independently.
Exclusion criteria
Exclusion criteria: 1. Impaired consciousness, or significant cognitive, linguistic, or communicative deficits that would invalidate informed consent or preclude meaningful participation. 2. Severe visual, auditory, or motor impairments that would substantially interfere with performing study-specific procedures. 3.Demonstrated inability or unwillingness to commit to and comply with the complete 6-month structured training and follow-up protocol. 4.Presence of multiple uncontrolled systemic comorbidities, active malignancy (except localized non-melanoma skin cancer), or clinically significant dysfunction of major organ systems. 5. Concurrent active respiratory pathologies that could interfere with pulmonary function test interpretation or confound COPD assessment. 6.Documented history of non-adherence to medical care, anticipated poor protocol compliance, or explicit refusal to participate in the pharmacist-led intervention. 7.Active or inadequately controlled psychiatric disorders that, in the investigator’s judgment, could compromise decision-making capacity, adherence, or safety.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome was the rate of improper inhaler use, including technique errors and inappropriate device selection.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Medication adherence, as assessed by the Morisky Medication Adherence Scale (MMAS), with scores ranging from 0 to 8.;The mean CAT score;Number of moderate-to-severe acute exacerbations during the study period.;Lung function status; | — |
Countries
China
Contacts
Public ContactHuabo Wei
Fengdu County People's Hospital
Outcome results
None listed